FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
Rewiring Sight with Nanowires: Vision Restored and Infrared Detected in Primate Models
Innovative nanoprosthesis delivers visible and infrared vision in early studies A retinal nanoprosthesis made from tellurium nanowires restored partial sight…
popular posts
![[Newsroom] Thumbnail GLP1 and AMD Story](https://piemagazine.org/wp-content/uploads/sites/4/2025/06/Newsroom-Thumbnail-GLP1-and-AMD-Story-579x326.png)
latest posts
